Age, GH/IGF-1 Levels, Tumor Volume, T2 Hypointensity, and Tumor Subtype Rather Than Proliferation and Invasion Are All Reliable Predictors of Biochemical Response to Somatostatin Analogue Therapy in Patients With Acromegaly: A Clinicopathological Study

Abstract

Purpose: To determine whether biochemical responses to long-acting forms of first-generation somatostatin analogue (SSA) therapy in patients with acromegaly could be predicted from baseline and postoperative hor-mone concentrations, and tumor radiological and histopathological characteristics.Methods: A total of 68 patients with acromegaly for whom postoperative SSA therapy was started were cate-gorized according to their responses to treatment (SSA-responders vs. non-responders). The patients were compared based on their demographic characteristics, hormone levels, magnetic resonance imaging (MRI), and histopathological findings. Receiver-operating-characteristic (ROC) curves were constructed using the predictive factors that were significant in the univariate analysis to determinate the optimal cut-off values.Results: The SSA-responders were significantly older (p = 0.041). Lower GH at diagnosis (p = 0.036), the post-operative 1st-week GH level (p = 0.027), baseline GH, insulin-like growth factor-1 (IGF-1) and IGF-1% upper limit of normal (ULN) (p = 0.001, p = 0.006, p = 0.023, respectively) were associated with biochemical response. T2-hypointensity and lower tumor volume were more common in the SSA-responders (p = 0.018, p = 0.03, respectively). Compared to sparsely granulated somatotroph tumors, densely granulated somatotroph tumors and other PitNETs causing GH excess including mammosomatotroph and mixed somatotroph and lactotroph tumors were more likely to respond to SSA therapy (p = 0.026, p = 0.03, respectively). The cut-off values generated by ROC curve analysis were GH at diagnosis of <= 8.8 ng/mL, GH at baseline of <= 2.69 ng/mL, IGF-1 at baseline <= 461.5 ng/mL, IGF-1% ULN at baseline <= 180.4%, and tumor volume of <= 1.11 cm3 (allp < 0.05). There were no differences between the groups in terms of tumor invasiveness, proliferative activity (mitotic count per 2 mm2 and Ki-67 labeling index) and quantitative analyses of T2-weighted MRI.Conclusion: This study underscores that advanced age, low baseline GH and IGF-1 at diagnosis, low tumor vol-ume, densely granulated tumor subtype, and T2 hypointensity may help predict biochemical response to SSA therapy in cases of acromegaly. These variables should be assessed with utmost attention for all patients prior to SSA treatment. In cases of possible resistance to SSA therapy, therapeutic activity should be monitored more closely and other therapies should be administered immediately in the event of poor response.